Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
RedHill Biopharma Ltd. (RDHL)
Price$0.7244Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $286,000 | $8.0M | $6.5M | $61.8M | $85.8M | $64.4M | $6.3M | $8.4M | $4.0M | $101,000 | $3,000 |
| Gross profit | — | $4.9M | $3.1M | $28.5M | $36.4M | $27.5M | $4.0M | $5.5M | $1.9M | $101,000 | $3,000 |
| Gross margin | — | 60.31% | 47.03% | 46.06% | 42.39% | 42.68% | 64.09% | 66.06% | 46.94% | 100.00% | 100.00% |
| Research & development | $2.0M | $1.6M | $3.5M | $7.3M | $29.5M | $16.5M | $17.4M | $24.9M | $33.0M | $25.2M | $17.8M |
| Operating expenses | $8.2M | $19.5M | $9.5M | $71.3M | $117.5M | $91.2M | $47.2M | $44.9M | $53.9M | $30.6M | $22.0M |
| Operating income | −$7.9M | −$14.6M | $12.6M | −$42.8M | −$81.1M | −$63.7M | −$43.2M | −$39.3M | −$52.0M | −$30.5M | −$22.0M |
| Operating margin | −2,765.38% | −181.69% | 193.45% | −69.33% | −94.61% | −98.95% | −686.71% | −470.47% | −1,297.03% | −30,240.59% | −733,400.00% |
| EBITDA | −$7.7M | −$14.0M | $14.1M | −$40.7M | −$79.2M | −$62.0M | −$42.2M | −$39.0M | — | — | — |
| EBITDA margin | −2,675.52% | −174.38% | 215.57% | −65.87% | −92.38% | −96.29% | −670.86% | −466.39% | — | — | — |
| Net income | −$429,000 | −$8.3M | $23.9M | −$71.7M | −$97.7M | −$76.2M | −$42.3M | −$38.8M | −$45.5M | −$29.4M | −$21.1M |
| Net profit margin | −150.00% | −102.80% | 366.25% | −115.97% | −113.98% | −118.36% | −672.45% | −464.35% | −1,136.61% | −29,079.21% | −703,000.00% |
| Basic EPSper basic share | — | $0.00 | $0.01 | -$0.12 | -$0.21 | -$0.21 | -$0.14 | -$0.17 | -$0.26 | -$0.23 | -$0.19 |
| Diluted EPSper diluted share | — | $0.00 | $0.01 | -$0.12 | -$0.21 | -$0.21 | -$0.14 | -$0.17 | -$0.26 | -$0.24 | -$0.19 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Ben-Asher Dror | 441.35M |
Scruggs Rick D | 312.5M |
Goldberg Guy Joel | 305.72M |
Ingber Razi | 277.56M |
Frish Adi | 276.81M |
Raday Gilead | 261.06M |
Tsimchi Ofer | 146.25M |
Cabilly Shmuel | 105.2M |
Reed Kenneth | 105.2M |
Mamluk Roni | 103.5M |
Yorkville Advisors Global, LP | 122.13K |
GAGNON SECURITIES LLC | 88.41K |
CITADEL ADVISORS LLC | 65.32K |
RHUMBLINE ADVISERS | 13.76K |
Lido Advisors, LLC | 11.01K |
GAMMA Investing LLC | 6.96K |
CITIGROUP INC | 4.38K |
Federation des caisses Desjardins du Quebec | 3.39K |
ROYAL BANK OF CANADA | 351 |
UBS Group AG | 100 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 6, 2026Form 4 | Raday GileadChief Operating Officer | SellOrdinary Shares | 15.74M | $0.00 | $0.00 | 261.06M |
Community posts
RedHill reports wider first-half loss amid commercial-portfolio transition
RedHill Biopharma ($RDHL) reported a first-half net loss of $6.1 million, compared with $4.1 million a year earlier, and no revenue from continuing operations. Operating cash use was $4.6 million, while the half-year cash balance stood at $ ...
